Ugur Sahin Sells 20,500 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 20,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00. Following the transaction, the chief executive officer owned 688,209 shares in the company, valued at $66,281,408.79. This represents a 2.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Stock Up 0.3%

BNTX stock traded up $0.33 during trading on Friday, reaching $96.73. 1,176,224 shares of the stock were exchanged, compared to its average volume of 1,110,613. The firm’s 50 day moving average is $97.00 and its 200 day moving average is $95.37. The firm has a market cap of $24.46 billion, a P/E ratio of -12.35 and a beta of 1.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue was down 59.5% on a year-over-year basis. During the same period last year, the business posted ($1.60) EPS. As a group, research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Monday, June 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Canaccord Genuity Group decreased their target price on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Finally, Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently bought and sold shares of the stock. Flossbach Von Storch SE purchased a new stake in BioNTech in the 2nd quarter valued at $207,142,000. BNP Paribas Financial Markets boosted its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after acquiring an additional 166,432 shares during the last quarter. GSK plc bought a new stake in shares of BioNTech in the 4th quarter worth $84,711,000. Finally, First Trust Advisors LP grew its stake in shares of BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.